The diagnostic performance in clinically significant prostate cancer with PI-RADS version 2.1: simplified bpMRI versus standard mpMRI

被引：0
|
作者：
Jihui Song
Chenglin Zhao
Fei Zhang
Yingdi Yuan
Lee M. Wang
Vivek Sah
Jun Zhang
Wencai Weng
Zhenghan Yang
Zhenchang Wang
Liang Wang
机构：
[1] Beijing Friendship Hospital,Department of Radiology
[2] Capital Medical University,Department of Radiology
[3] Dalian University Affiliated Xinhua Hospital,Department of Radiology
[4] QUFU City People Hospital,Department of Radiology
[5] Ganzhou District People’s Hospital,Department of Radiology
[6] Carnegie Mellon University,undefined
[7] ADK Hospital,undefined
[8] The First Hospital of Qinhuangdao,undefined
来源：
Abdominal Radiology | 2023年 / 48卷
关键词：
PI-RADS; Prostate cancer; Screening; Simplified biparametric MRI; Multiparametric MRI; Abbreviated protocol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：704 / 712
页数：8
相关论文
共 50 条
  • [41] The Role of Radiomics in the Prediction of Clinically Significant Prostate Cancer in the PI-RADS v2 and v2.1 Era: A Systematic Review
    Antolin, Andreu
    Roson, Nuria
    Mast, Richard
    Arce, Javier
    Almodovar, Ramon
    Cortada, Roger
    Maceda, Almudena
    Escobar, Manuel
    Trilla, Enrique
    Morote, Juan
    CANCERS, 2024, 16 (17)
  • [42] Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
    Li, Tianping
    Sun, Linna
    Li, Qinghe
    Luo, Xunrong
    Luo, Mingfang
    Xie, Haizhu
    Wang, Peiyuan
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [43] Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study
    Cai, Guan-Hui
    Yang, Qi-Hua
    Chen, Wen-Bo
    Liu, Qing-Yu
    Zeng, Yu-Rong
    Zeng, Yu-Jing
    CURRENT ONCOLOGY, 2021, 28 (03) : 1823 - 1834
  • [44] Biparametric MRI-based radiomics for prediction of clinically significant prostate cancer of PI-RADS category 3 lesions
    Lu, Feng
    Zhao, Yanjun
    Wang, Zhongjuan
    Feng, Ninghan
    BMC CANCER, 2025, 25 (01)
  • [45] Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
    Gomez-Gomez, Enrique
    Moreno Sorribas, Sara
    Valero-Rosa, Jose
    Blanca, Ana
    Mesa, Juan
    Salguero, Joseba
    Carrasco-Valiente, Julia
    Lopez-Ruiz, Daniel
    Jose Anglada-Curado, Francisco
    DIAGNOSTICS, 2021, 11 (08)
  • [46] Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer
    Tavakoli, Anoshirwan Andrej
    Hielscher, Thomas
    Badura, Patrick
    Goertz, Magdalena
    Kuder, Tristan Anselm
    Gnirs, Regula
    Schwab, Constantin
    Hohenfellner, Markus
    Schlemmer, Heinz-Peter
    Bonekamp, David
    RADIOLOGY, 2023, 306 (01) : 186 - 199
  • [47] Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience
    Byun, Jieun
    Park, Kye Jin
    Kim, Mi-hyun
    Kim, Jeong Kon
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2020, 52 (02) : 577 - 586
  • [48] Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
    Junker, Daniel
    Schaefer, Georg
    Edlinger, Michael
    Kremser, Christian
    Bektic, Jasmin
    Horninger, Wolfgang
    Jaschke, Werner
    Aigner, Friedrich
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [49] Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer
    Zhang, Yu
    Zeng, Na
    Zhu, Yi Chen
    Huang, Yang Xin Rui
    Guo, Qiang
    Tian, Ye
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [50] Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer
    Yu Zhang
    Na Zeng
    Yi Chen Zhu
    Yang Xin Rui Huang
    Qiang Guo
    Ye Tian
    World Journal of Surgical Oncology, 16
12345